Experiment 69612
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Hypericum perforatum (CLUSIACEAE) |
| Citation | HENDERSON,L: YUE,QY: BERGQUIST,C: GERDEN,B: ARLETT,P:. (2002). ST JOHN'S WORT (HYPERICUM PERFORATUM): DRUG INTERACTIONS AND CLINICAL OUTCOMES.. 54(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | MIGRAINE WERE IDENTIFIED. THESE INTERACTIONS ARE ASSOCIATED WITH AN INCREASED RISK OF ADVERSE REACTIONS. THE VARIABLE QUALTY AND QUANTITY OF CONSTITUENTS IN SJW PREPARATIONS. IN ADDITION, POSSIBLE PHARMACODYNAMIC INTERACTIONS WITH SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS AND SEROTONIN (5-HT(1D)) RECEPTOR-AGONISTS SUCH AS TRIPTANS USED TO TREAT MEDICINES. THESE INTERACTIONS ARE PROBABLY DUE TO THE INDUCTION OF CYTOCHROME P450 ISOENZYMES CYP3A4, CYP2C9, CYP1A2 AND THE TRANSPORT PROTEIN P-GLYCOPROTEIN BY CONSTITUENTS IN SJW. THE DEGREE OF INDUCTION IN UNPREDICTABLE DUE TO FACTORS SUCH AS CANT INTERACTIONS HAVE BEEN INDENTIFIED WITH PRECRIBED MEDICINES INCLUDING WARFARIN, PHENPROCOUMON, CYCLOSPORIN, HIV PROTEASE INHIBITORS, THEOPHYLLINE, DIGOXIN AND ORAL CONTRACEPTIVES RESULTING IN A DECREASE IN CONCENTRATION OR EFFECT OF THE A SYSTEMIC REVIEW OF ALL THE AVAILABLE EVIDENCE, INCLUDING WORLDWIDE PUBLISHED LITERATURE AND SPONTANEOUS CASE REPORTS PROVIDED BY HEALTHCARE PROFESSIONALS AND REGULATORY AUTHORITIES WITHIN EUROPE WAS UNDERTAKEN. A NUMBER OF CLINICALLY SIGNIFI |
| Dose amount | 900.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | HYDRO-ALCOHOLIC EXT |
| Gender | GIVEN TO BOTH SEXES |